Condition
Leukemia, T Cell
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Unknown2
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04938115Not ApplicableCompletedPrimary
Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia
NCT04090268Not ApplicableRecruiting
Precision Exercise in Children With Malignant Hemopathies
NCT03564704Phase 2Unknown
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
NCT03553238Phase 2Unknown
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Showing all 4 trials